wherein R_{11a} is H; C_{1-10} alkyl; C_6 aryl; C_{7-10} alkylaryl; C_{3-7} cycloalkyl or C_{4-8} (alkylcycloalkyl) optionally substituted with carboxyl; or heterocycle-C_{1-6} alkyl;

and R_{11b} is C_{1-6} alkyl substituted with carboxyl, (C_{1-6} alkoxy)carbonyl or phenylmethoxycarbonyl; or C_{7-16} aralkyl substituted on the aromatic portion with carboxyl, (C_{1-6} alkoxy)carbonyl or phenylmethoxycarbonyl;

or R_{11a} and R_{11b} are joined to form a 3 to 7-membered nitrogen-containing ring optionally substituted with carboxyl or (C_{1-6} alkoxy) carbonyl;

or

b) when Q is N-Y, a is 0 or 1, b is 0 or 1, and

B is H, an acyl derivative of formula R_{11}-C(O)- or a sulfonyl of formula R_{11}-SO_2 wherein

R_{11} is (i) C_{1-10} alkyl optionally substituted with carboxyl or C_{1-6} alkanoyloxy, C_{1-6} alkoxy, or carboxyl substituted with 1 to 3 C_{1-6} alkyl substituents;

(ii) C_{3-7} cycloalkyl or C_{4-10} alkylcycloalkyl, both optionally substituted with carboxyl, (C_{1-6} alkoxy)carbonyl or phenylmethoxycarbonyl;

(iii) C_6 or C_{10} aryl or C_{7-16} aralkyl optionally substituted with C_{1-6} alkyl, hydroxy, or amino optionally substituted with C_{1-6} alkyl; or

(iv) Het optionally substituted with C_{1-6} alkyl, hydroxy, amino optionally substituted with C_{1-6} alkyl, or amido optionally substituted with C_{1-6} alkyl,



or

R_6, when present, is C_{1-6} alkyl substituted with carboxyl;

R_5, when present, is C_{1-6} alkyl optionally substituted with carboxyl;

and

c) when Q is either CH_2 or N-Y, then

R_4 is C_{1-10} alkyl, C_{3-7} cycloalkyl or C_{4-10} (alkylcycloalkyl);

z is oxo or thioxo;

R_3 is C_{1-10} alkyl optionally substituted with carboxyl, C_{3-7} cycloalkyl or C_{4-10} (alkylcycloalkyl);

W is a group of formula II:



Formula II

wherein R_2 is C_{1-10} alkyl or C_{3-10} cycloalkyl optionally substituted with carboxyl or an ester or amide thereof; C_6 or C_{10} aryl or C_{7-16} aralkyl; or

W is a group of formula IIa:



Formula IIa

wherein X is CH or N; and

R_{2a} is divalent C_{3-4} alkylene which together with X and the carbon atom to which X and R_{2a} are attached form a 5- or 6-membered ring, said ring optionally substituted with OH; SH; NH_2; carboxyl; R_{12}; CH_2-R_{12}, OR_{12}, $C(O)OR_{12}$, SR_{12}, NHR_{12} or $NR_{12}R_{12a}$[:] ;

wherein R_{12} and R_{12a} are independently a saturated or unsaturated C_{3-7} cycloalkyl or C_{4-10} (alkyl cycloalkyl) being optionally mono-, di- or tri-substituted with R_{15},

or R_{12} and R_{12a} is a C_6 or C_{10} aryl or C_{7-16} aralkyl optionally mono-, di- or tri-substituted with R_{15}, or R_{12} and R_{12a} is Het or (lower alkyl)-Het optionally mono-, di- or tri-substituted with R_{15},

wherein each R_{15} is independently C_{1-6} alkyl; C_{1-6} alkoxy; amino optionally mono- or di-substituted with C_{1-6} alkyl; sulfonyl; NO_2; OH; SH; halo; haloalkyl; amido optionally mono-substituted with C_{1-6} alkyl, C_6 or C_{10} aryl, C_{7-16} aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C_6 or C_{10} aryl, C_{7-16} aralkyl or

Het, said aryl, aralkyl or Het being optionally substituted with R_{16};

wherein R_{16} is C_{1-6} alkyl; C_{1-6} alkoxy; amino optionally mono- or di-substituted with C_{1-6} alkyl; sulfonyl; NO_2; OH; SH; halo; haloalkyl; carboxyl; amide; or (lower alkyl)amide;

or X is CH or N; and R_{2a} is a divalent C_{3-4} alkylene which together with X and the carbon atom to which X and R_{2a} are attached form a 5- or 6-membered ring which in turn is fused with a second 5-, 6- or 7-membered ring to form a bicyclic system wherein the second ring is substituted with OR_{12a}, wherein R_{12a} is C_{7-16} aralkyl;

R_{1a} is hydrogen, and R_1 is the side chain of an amino acid selected from the group consisting of cysteine (Cys), aminobutyric acid (Abu), norvaline (Nva) and allylglycine (AlGly); or

R_{1a} and R_1 together form a 3- to 6-membered ring optionally substituted with R_{14} wherein R_{14} is C_{1-6} alkyl, C_{3-5} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_6 aryl or C_{7-10} aralkyl all optionally substituted with halo; and

A is hydroxy [or a pharmaceutically acceptable salt of ester thereof]; or C_{1-6} alkylamino, di(C_{1-6} alkyl)amino or phenyl-C_{1-6} alkylamino;

or a pharmaceutically acceptable salt or ester thereof.

Claim 23, line 7 (page 153, line 4), after "position with" insert --R_{13}, wherein --;

line 8 (page 153, line 5), after "or 2, and" delete -- R_{13}, wherein --.

Claim 32, line 3, delete "all of which" and insert --each of which is--.

40. (Amended) A compound of formula (IA) [including] or the racemates, diastereoisomers [and] or optical isomers thereof



(IA)

wherein Y is H or C_{1-6} alkyl;

a is 0 or 1;

b is 0 or 1;

B is as defined in claim 1, paragraph b);

R_6, R_5, R_4, z, R_3, W, R_1, R_{1a} and A are as defined in claim 1.

---

45. (Amended) A compound of formula IB [including] or the racemates, diastereoisomers [and] or optical isomers thereof:



(IB)

wherein

B, a, b, R_6, R_5, Y, R_4, Z, R_3, and A are as defined in claim 1,

R_{13} is R_{12}, OR_{12}, $C(O)OR_{12}$, SR_{12}, NHR_{12} or $NR_{12}R_{12}$, wherein R_{12} and R_{12} are as defined in claim 1; and

R_{14} is C_{1-6} alkyl, C_{2-6} alkenyl optionally substituted with halogen; C_{6-10} aryl or C_{7-10} aralkyl optionally substituted with halogen; or a pharmaceutically acceptable salt or ester

thereof.

Claim 54, line 2, delete "naphtylmethoxy" and insert --naphthylmethoxy--.

Claim 58, line 1, delete "the P1 segment" and insert --P1--.

Claims 59 and 60, line 1 of each claim, delete "said P1 segment" and insert --P1--.

Claim 61, delete "said asymmetric carbon at position 1" and insert --the C_1 carbon atom--

Claim 63, line 2, delete "all of which" and insert --each of which is--.

67. (Amended) A compound of formula IC [including] <u>or the</u> racemates, diastereoisomers [and] <u>or</u> optical isomers <u>thereof</u>:



(IC)

wherein B is as defined in claim 1, paragraph a);

R_4, R_3, W, R_{1a}, R_1, and A are as defined in claim 1.

Claim 96, line 2, delete "therapeutically" and insert --pharmaceutically--.